Theratechnologies Announces Financial Results for Second Quarter of 2014
Marketwire - Wed Jul 09, 5:45AM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the second quarter ended May 31, 2014.
Theratechnologies to Announce Financial Results for the Second Quarter of 2014
Marketwire - Wed Jul 02, 3:20PM CDT
Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the second quarter ended May 31, 2014, on Wednesday, July 9, 2014, before markets open.
IIROC Trade Resumption - TH
CNW Group - Wed Jun 25, 8:31AM CDT
Trading resumes in:
IIROC Trading Halt - TH
CNW Group - Wed Jun 25, 8:28AM CDT
The following issues have been halted by IIROC:
Theratechnologies to Receive 4.1 Million Dollar Payment from Revenue Canada
Marketwire - Wed Jun 25, 8:05AM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it will receive a refund of approximately $4.1 million from the Canada Revenue Agency after settling a dispute over its claims of refundable investment tax credits related to its 1994 and 1995 taxation years.
Theratechnologies Obtains U.S. Patent Term Extension for Tesamorelin
Marketwire - Mon Jun 09, 5:00PM CDT
Theratechnologies Inc. (TSX: TH) today announced that the United States Patent and Trademark Office (USPTO) has issued a patent term extension certificate for tesamorelin, the Company's principal compound. Pursuant to this certificate, the USPTO has extended the term of US patent No. 5,861,379 (tesamorelin composition of matter patent) by five years. This patent was originally set to expire in May 2015 and is now set to expire in May 2020.
Additional Update on Availability of EGRIFTA(R) (tesamorelin for injection) in the United States
Marketwire - Fri May 23, 5:46AM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced today that following further communications between the United States Food and Drug Administration (FDA) and the Company it is revisiting the information provided in its May 20, 2014 press release regarding the release of the 2mg/vial presentation of EGRIFTA(R) (tesamorelin for injection) which was initially planned for the early part of June. Accordingly, based on such communications, Theratechnologies is no longer able to determine a timeline or whether such presentation will be released for use.
Announcements in Conjunction With Theratechnologies Annual Meeting
Marketwire - Wed May 21, 10:32AM CDT
Theratechnologies Inc. (TSX: TH) today held its annual meeting of shareholders, chaired by Dawn Svoronos, chair of the board of Theratechnologies.
Theratechnologies Inc.: Update on Availability of EGRIFTA(TM) in the United States
Marketwire - Tue May 20, 4:41PM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it will be releasing additional limited supplies of the 2 mg/vial presentation of EGRIFTA(TM) (tesamorelin for injection) in the early part of June. This comes as a result of on-going communications with the FDA and a Company determination that there is a critical need to maintain the supply for existing patient use. This will allow the Company to help patients stay on therapy during the production stoppage.
Theratechnologies Announces Financial Results for Fiscal Year 2013
Marketwire - Thu Feb 27, 6:02AM CST
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the year ended November 30, 2013.